MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Endocyte Company Profile (NASDAQ:ECYT)

Consensus Ratings for Endocyte (NASDAQ:ECYT) (?)
Ratings Breakdown: 2 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $14.33 (180.50% upside)

Analysts' Ratings History for Endocyte (NASDAQ:ECYT)
Show:
DateFirmActionRatingPrice TargetActions
3/3/2015WedbushSet Price TargetBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2014Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2014Citigroup Inc.Reiterated RatingNeutral$8.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/25/2014Chardan CapitalReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2014Cantor FitzgeraldInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/30/2014Chardan CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/8/2014Brean CapitalInitiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2014Chardan CapitalLower Price TargetBuy$26.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2014RBC CapitalLower Price TargetOutperform$20.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/5/2014Citigroup Inc.Initiated CoverageNeutral$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2014Chardan CapitalLower Price TargetBuy$43.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2014RBC CapitalLower Price TargetOutperform$46.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2014Brean CapitalLower Price TargetBuy$41.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2014Piper JaffrayDowngradeOverweight -> Neutral$13.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2014Robert W. BairdDowngradeOutperform -> Neutral$36.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2014WedbushReiterated RatingOutperform$23.00 -> $65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/25/2014Chardan CapitalBoost Price TargetBuy$20.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2014Roth CapitalBoost Price Target$20.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2014Brean CapitalBoost Price TargetBuy$21.00 -> $41.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2014Piper JaffrayBoost Price TargetOverweight$17.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/21/2014Credit SuisseBoost Price TargetOutperform$24.00 -> $44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2014Leerink SwannLower Price Target$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/2/2013Piper JaffrayInitiated CoverageOverweight$17.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2013Chardan CapitalInitiated CoverageBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/16/2013Brean CapitalInitiated CoverageBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/5/2013Credit SuisseBoost Price TargetOutperform$16.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 8/3/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha